Lower Prognostic Performance of the International Metabolic Prognostic Index Compared to the Conventional IPI and NCCN-IPI in a Real-World Cohort of Diffuse Large B-Cell Lymphoma

作者
Daisuke Ikeda,Mitsuaki Oura,Atsushi Uehara,Rikako Tabata,Kentaro Narita,Masami Takeuchi,Youichi Machida,Kosei Matsue
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 4493-4493
标识
DOI:10.1182/blood-2023-189352
摘要

Introduction: The international metabolic prognostic index (IMPI) is a recently proposed model that shows improved outcome prediction for patients with diffuse large B-cell lymphoma (DLBCL) compared to the International Prognostic Index (IPI) (Mikhaeel et al.). IMPI combines total metabolic tumor volume (TMTV) as continuous variables with clinical factors, allowing individualized prognosis estimation. However, the applicability of IMPI to routine clinical practice remains uncertain since the model construction was based on data from clinical trials. Furthermore, the comparison of the model performance between IMPI and the National Comprehensive Cancer Network IPI (NCCN-IPI) is not reported so far. Methods: We performed retrospective analysis of consecutive patients with newly diagnosed DLBCL who were initially treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) at Kameda Medical Center between 2006 and 2020. Patients who had no fluorodeoxyglucose-avid lesions were excluded. TMTV was defined as the volume of lymphoma-associated lesions with a standardized uptake value of ≥4 as the absolute threshold (Metavol, Hokkaido University, Japan). According to the original study (Mikhaeel et al.), IMPI was calculated using the following formula: 0.003077330 × (MTV lower than the median of 307.9ml) - 0.002761985 × (MTV higher than the median of 307.9ml) + 0.008092449 × Age -0.114645415 × Stage 2 + 0.281141117 × Stage 3 + 0.322247142 × Stage 4. The receiver operating curve (ROC) for predicting 5-year survival was compared among IMPI-, IPI-, and NCCN-IPI-based classifications. The predictive performance of these three systems was evaluated using the Akaike information criterion (AIC) and Harrell's concordance index (c-index). Results: A total of 314 patients were included in the study. The median age was 72 years old (interquartile range [IQR] 64-79), which was younger than the original data (median 62, IQR 51-70). Regarding the distributions of IPI risk groups, this cohort had a lower number of low-risk patients (27.0% vs. 32.4%) and a higher number of high-risk patients (23.9% vs. 19.5%). The median TMTV was 168 (IQR 47-530), which was approximately two times lower than that in the original study (median 307, IQR 77-838). After calculating and ranking the individual IMPI scores, nearly half of the patients (n=147, 46.8%) were reclassified into different risk groups from the original IPI categories (Figure 1); 76 (51.7%) were upstaged, and 71 (48.3%) were downstaged. Of note, the reclassification resulted in a significantly better OS prediction only for the IPI high-risk group (5-year OS rate, IMPI high-risk vs. IMPI not high-risk, 41.9% vs. 59%, P =0.042), while it did not for the IPI low-, low-intermediate-, and high-intermediate-risk groups. The area under the curve (AUC) from the ROC curve predicting 5-year survival was not significantly different between IMPI- (AUC 0.65) and either IPI- (AUC 0.67, P =0.42) or NCCN-IPI-categories (AUC 0.68, P=0.25). Finally, the predictive performance and model fitness were compared among these three indices. IMPI had the highest AIC (1117.68) and the lowest c-index (0.643) for OS prediction, whereas NCCNIPI yielded the best performance (AIC 1097.66 and c-index 0.677) (Table 1). Conclusions: We demonstrated that the IMPI model did not outperform the conventional IPI and NCCN-IPI systems in a real-world cohort of DLBCL patients. The difference in age and tumor burden, which are the major components of IMPI, may lead to poorer prognostic performance. Further large-scale studies are warranted to validate the prognostic value of IMPI outside of clinical trials.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
泽ze完成签到 ,获得积分10
刚刚
WANG完成签到,获得积分10
2秒前
希望天下0贩的0的应助被gl6542采纳,获得10
3秒前
牛牛完成签到,获得积分10
4秒前
乐观友菱完成签到,获得积分10
5秒前
123完成签到,获得积分10
6秒前
光亮的小甜瓜完成签到 ,获得积分10
6秒前
贤惠的咖啡完成签到,获得积分10
6秒前
橘子女王完成签到 ,获得积分10
7秒前
沉静觅风完成签到,获得积分10
8秒前
9秒前
林好人完成签到 ,获得积分10
12秒前
firewood完成签到,获得积分10
12秒前
魁梧的芷完成签到,获得积分10
13秒前
16秒前
咎青文完成签到,获得积分10
18秒前
20秒前
Che完成签到 ,获得积分10
21秒前
自然完成签到,获得积分10
21秒前
整齐盼烟完成签到,获得积分10
22秒前
leicaixia完成签到 ,获得积分10
29秒前
陶醉的星月完成签到,获得积分10
29秒前
章鱼行者完成签到,获得积分10
32秒前
安静的幻天完成签到 ,获得积分10
32秒前
36秒前
38秒前
Yanping完成签到,获得积分10
38秒前
kelite完成签到 ,获得积分10
43秒前
yuan完成签到 ,获得积分10
46秒前
bao完成签到,获得积分10
47秒前
Tristan完成签到 ,获得积分10
50秒前
羡恋完成签到 ,获得积分10
50秒前
CowPageant完成签到,获得积分10
51秒前
410的大平层有213个杀手完成签到 ,获得积分10
51秒前
Laser_eyes完成签到,获得积分10
51秒前
死糊完成签到,获得积分10
52秒前
大西瓜完成签到 ,获得积分10
52秒前
Tonald Yang发布了新的文献求助10
54秒前
wzk完成签到 ,获得积分10
54秒前
54秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180084
求助须知:如何正确求助?哪些是违规求助? 9570230
关于积分的说明 21808824
捐赠科研通 7776113
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557454
邀请新用户注册赠送积分活动 2479012